Overview
- Shares jumped about 22% after the company posted results above forecasts and raised guidance.
- Adjusted EPS came in at $1.27 on revenue of $327.3 million, with sales down 5.3% year over year.
- Full-year adjusted EPS guidance increased to a $4.90 midpoint.
- Operating margin expanded to 17.9% from 15% a year ago, and free cash flow reached $106.3 million.
- Management cited plasma collection share gains, Blood Management Technologies growth, a heparinase cartridge rollout in Europe and Japan, and the planned Vivasure acquisition as upcoming growth drivers.